Clinical Trial Update: Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of carfilzomib, pomalidomide, and dexamethasone in high-risk multiple myeloma; the study is currently active but not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Kyprolis (carfilzomib) (carfilzomib)
• Pomalyst (pomalidomide) (pomalidomide)

Snippet

Sponsor: Emory University | Conditions: Plasma Cell Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING